title: Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
abstract: OBJECTIVE
  To evaluate complications of intraperitoneal ports placed laparoscopically as a separate procedure after initial debulking surgery for ovarian, fallopian tube, or primary peritoneal cancer.
  
  
  METHODS
  A retrospective case series (Canadian Task Force Classification III).
  
  
  METHODS
  Inpatient, academic teaching institution.
  
  
  METHODS
  Female patients of any age, at a single institution, undergoing laparoscopically-assisted intraperitoneal port placement after initial surgery for ovarian, fallopian tube, or primary peritoneal cancer from January 2001 through December 2009.
  
  
  METHODS
  Laparoscopically assisted intra-peritoneal port placement.
  
  
  RESULTS
  Thirty-three ports were successfully placed, with no conversions to laparotomy. Only 2 patients were unable to receive intraperitoneal chemotherapy, and there was 1 major complication (enterotomy) related to port placement. There were 6 cases of port dysfunction (17%); however, in 3 cases the port was replaced and subsequently functioned well. There were 2 cases of port infection necessitating port removal. The majority (81.8%) of patients were able to complete all planned cycles of intraperitoneal chemotherapy.
  
  
  CONCLUSIONS
  Based on the data from our institution, laparoscopic placement of an intraperitoneal port may be safely performed as a second procedure after initial surgery for stage III ovarian, fallopian tube, or primary peritoneal cancer and provides access for post-operative therapy.
authors.affiliation: Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
authors.forename: Jo Marie Tran
authors.initials: JM
authors.lastname: Janco
authors.forename: Michele R
authors.initials: MR
authors.lastname: Hacker
authors.forename: Panagiotis A
authors.initials: PA
authors.lastname: Konstantinopoulos
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Cannistra
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Awtrey
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002408:Catheters, Indwelling; D002945:Cisplatin / Q000627:therapeutic use; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D010535:Laparoscopy / Q000379:methods*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D017239:Paclitaxel / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D010537:Peritoneum / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D002945:Cisplatin